To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.

There was no significant difference in survival outcomes for patients with advanced neuroendocrine tumors who were treated with low-dose everolimus compared to standard-dose everolimus, according to a ...

Researchers explored whether a direct-to-patient digital intervention could increase the number of lung cancer screening CTs among patients in 2 US health systems.

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

HealthDay News — Multicancer early detection (MCED) tests can increase earlier-stage diagnoses and reduce late-stage diagnoses, according to a study published online Nov. 10 in Cancer.